Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.21.2
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Feb. 03, 2020
USD ($)
milestone
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
therapy
Aug. 31, 2017
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Aug. 31, 2019
USD ($)
Operating Leased Assets [Line Items]                                  
General and administrative expense         $ 6,618,000 $ 6,101,000   $ 11,530,000 $ 8,777,000                
Payment received   $ 2,000,000.0                              
Period after public launch to terminate agreement   3 years                              
Percentage of net present value of royalty payments   75.00%                              
Aevi                                  
Operating Leased Assets [Line Items]                                  
Milestone payment               0                  
Aevi                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone 2                                
Contingent consideration $ 6,500,000           $ 6,500,000                    
Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone 3                                
Contingent consideration     $ 15,000,000.0                            
Milestone payment               0                  
CERC-801, CERC-802, and CERC-803 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy     3                            
CERC-913 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy     1                            
Milestone One | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration $ 2,000,000.0                                
Milestone One | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                     $ 6,000,000.0            
Milestone Two | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration $ 4,500,000                                
Milestone Two | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 5,000,000.0          
Milestone Three | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 4,000,000.0          
Alto | CERC-301 Out-License                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                             $ 18,600,000    
Revenue recognized from milestones to date         0     0                  
ES | CERC-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Revenue recognized from milestones to date         0     0                  
ES | CERC-611 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                                 $ 20,000,000.0
Revenue recognized from milestones to date         0     0                  
ES | Milestone One | CERC-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 6,000,000.0      
ES | Milestone Two | CERC-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 20,000,000.0      
Janssen Pharmaceuticals, Inc. (Janssen) | CERC-501                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones       $ 20,000,000.0                          
Revenue recognized from milestones to date         0     0                  
Proceeds from sale       $ 25,000,000.0                          
Karbinal Agreement | TRIS Pharma                                  
Operating Leased Assets [Line Items]                                  
Minimum quantity required | unit                   70,000              
Make whole payment per unit (in dollars per share) | $ / shares                   $ 30              
CERC-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                               $ 10,000,000.0  
Percent of payments received from sublicensing                               30.00%  
Research and development expense               10,000,000.0                  
Cumulative expense recognized to date         0     0                  
CERC-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 112,500,000  
CERC-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 75,000,000  
CERC-006 Astellas License Agreement | Astellas Pharma, Inc. (Astellas)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee         500,000     500,000                  
Maximum aggregate milestone payment         5,500,000     5,500,000                  
Research and development expense               500,000                  
Cumulative expense recognized to date         500,000     500,000                  
CERC-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee         6,000,000.0     6,000,000.0                  
Research and development expense               0                  
Cumulative expense recognized to date         1,500,000     1,500,000                  
CERC-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment         71,500,000     71,500,000                  
CERC-007 AstraZeneca License Agreement | AstraZeneca plc (AstraZeneca) | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment         90,000,000.0     90,000,000.0                  
CERC-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                         $ 400,000        
Research and development expense         400,000     400,000                  
Cumulative expense recognized to date         0     0                  
Patent costs                         500,000        
General and administrative expense         $ 500,000     $ 500,000                  
CERC-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         24,200,000        
CERC-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         $ 50,000,000.0